Good info, looking for takeout Interesting information, Retired Cop, I have been thinking take-out for sometime simply because the new partnerships the company has talked about for the last two years have not materialized. If you analyze the ownership of the products in the company the only real product outside of Amorfix's control is the ALS antibody with Biogen. The parnership with Prevent on the Vaccine side gives Amorfix an option with a Revenue Sharing formula to take control after Phase 1 Clinical trials, which is a great deal for both Amorfix and Prevent. For the most part Amorfix's control of most products is wide open. So here is my dollar bet on a guess as to whats going to happen, if the company announces a Alzheimer's test 100 % probability of a take-out, I think their is a lower than 50% probability that the company continues with new partnerships, however their are creative ways in doing this that spreads the risk. Another scenario might be to sell off the Diagnostic side and keep the Therapuetic, should be seeing something soon.